Full history for every metric is available with a Kvantra account
Alpine Immune Sciences, Inc. (ALPN)
Key financial summary
Financials in USD| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 1 | 2 | 9 | 23 | 30 | 59 | 57 |
| Operating profit | $m | -44 | -51 | |||||
| Net profit | $m | -36 | -43 | -28 | -50 | -58 | -32 | -37 |
| EPS reported | $ | -0.64 | -0.69 | |||||
| Operating cashflow per share | $ | -1.58 | -1.58 | |||||
| Capex per share | $ | 0.01 | 0.01 | |||||
| FCF per share | $ | -1.59 | -1.59 | |||||
| Free cash flow | $m | -79 | -81 | |||||
| Net debt | $m | -317 | -306 | |||||
| Book value equity | $m | 328 | 333 | |||||
| Book value per share | $ | 6.56 | 5.20 | |||||
| Number of shares | m | 50 | 64.03 | |||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Value | ||||||||
| P/E TTM | x | - | - | |||||
| P/B LTM | x | 2.91 | 13.40 | |||||
| P/S LTM | x | 16.19 | 78.85 | |||||
| P/FCF LTM | x | -11.99 | -55.05 | |||||
| EV/EBITDA LTM | x | -29.26 | -101.01 | |||||
| EV/Sales LTM | x | 15.61 | 73.44 | |||||
| Earnings Yield LTM | % | -3.38% | -0.99% | |||||
| FCF Yield | % | -8.34% | -1.82% | |||||
| Quality | ||||||||
| ROE | % | -9.81% | -12.69% | |||||
| ROIC | % | -13.06% | -13.06% | |||||
| Operating margin | % | -75.16% | -75.16% | |||||
| Gross margin | % | -37.41% | -37.41% | |||||
| FCF/Sales | % | -135.03% | -135.03% | |||||
| Growth and momentum | ||||||||
| EPS Growth YoY | % | - | - | |||||
| Sales Growth YoY | % | +95.84% | +118.89% | |||||
| Net Income Growth YoY | % | - | - | |||||
| FCF Growth | % | - | - | |||||
| Operating Profit Growth | % | - | - | |||||
| Dividend and capital structure | ||||||||
| Dividend Yield | % | 0.00% | 0.00% | |||||
| Dividend Growth | % | 0.00% | 0.00% | |||||
| Payout Ratio | % | 0.00% | 0.00% | |||||
| FCF/Debt | x | -8.02 | -8.39 | |||||
| Net Debt/EBITDA | x | 1.08 | 1.08 | |||||
| EBIT/Net interest | x | -451.53 | -451.53 | |||||
| Net debt/market cap | % | -33.32% | -6.86% | |||||
| Net debt/Equity | x | -0.97 | -0.92 | |||||
| Gross debt/equity | x | 0.03 | 0.03 | |||||
Company overview
Alpine Immune Sciences, Inc. is a clinical-stage biopharmaceutical company focused on discovering and advancing protein-based immunotherapies. Their therapeutic endeavors address a range of conditions, including various cancers, autoimmune and inflammatory disorders, among others. The company's pipeline features ALPN-101, an ICOS/CD28 antagonist program being developed for autoimmune and inflammatory diseases; ALPN-202, a conditional CD28 costimulator and dual checkpoint inhibitor aimed at treating cancer; and ALPN-303, a dual B cell cytokine antagonist for B cell-mediated inflammatory and autoimmune conditions. Alpine Immune Sciences has established strategic collaborations, including an agreement with AbbVie Ireland Unlimited Company for the development of ALPN-101, and a partnership with Adaptimmune Therapeutics plc to create next-generation SPEAR T cell products. The company was founded in 2007 and operates from its headquarters in Seattle, Washington.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Alpine Immune Sciences, Inc. (ALPN)
Alpine Immune Sciences, Inc. is a clinical-stage biopharmaceutical company focused on discovering and advancing protein-based immunotherapies. Their therapeutic endeavors address a range of conditions, including various cancers, autoimmune and inflammatory disorders, among others. The company's pipeline features ALPN-101, an ICOS/CD28 antagonist program being developed for autoimmune and inflammatory diseases; ALPN-202, a conditional CD28 costimulator and dual checkpoint inhibitor aimed at treating cancer; and ALPN-303, a dual B cell cytokine antagonist for B cell-mediated inflammatory and autoimmune conditions. Alpine Immune Sciences has established strategic collaborations, including an agreement with AbbVie Ireland Unlimited Company for the development of ALPN-101, and a partnership with Adaptimmune Therapeutics plc to create next-generation SPEAR T cell products. The company was founded in 2007 and operates from its headquarters in Seattle, Washington.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free